Urologic Oncology-Seminars and Original Investigations

Papers
(The TQCC of Urologic Oncology-Seminars and Original Investigations is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Festschrift essay to celebrate Dr. Michael Droller61
Cover 2 - Masthead45
Genetic variations related to the prostate cancer risk: A field synopsis and revaluation by Bayesian approaches of genome-wide association studies40
GROWTH OF VON HIPPEL-LINDAU (VHL)-ASSOCIATED RENAL TUMORS DURING PREGNANCY39
UTILITY OF C-REACTIVE PROTEIN LEVELS IN IMPROVING RISK STRATIFICATION IN METASTATIC RENAL CELL CARCINOMA38
A QUALITATIVE EXPLORATION OF THE EXPERIENCE OF TRANSGENDER AND GENDER NONCONFORMING PATIENTS WITH GENITOURINARY AND GYNECOLOGIC MALIGNANCIES35
Extracellular vesicles in renal cell carcinoma: A review of the current landscape and future directions34
PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) patients. When is the optimal time point?33
Salvage local treatment for recurrent prostate cancer after focal therapy: A systematic review and meta-analysis32
Guideline discordant care in patients with metastatic germ cell tumors32
Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients32
Editorial Board31
Predictors of discharge to home following major surgery for urologic malignancies: Results from the national surgical quality improvement program30
Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites30
Radical prostatectomy readmissions: Causes, risk factors, national rates, & costs29
Poor clinical outcomes and immunoevasive contexture in SIRPα+ tumor-associated macrophages enriched muscle-invasive bladder cancer patients28
APPLICATION OF THE STRATCANS CRITERIA TO THE MUSIC AS COHORT: A STEP TOWARDS RISK STRATIFIED ACTIVE SURVEILLANCE27
NON-MUSCLE INVASIVE RECURRENCE AND MANAGEMENT DURING SURVEILLANCE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ACHIEVE CLINICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY26
PREOPERATIVE RADICAL CYSTECTOMY ERAS SCREENING AND EDUCATION – PATIENT REPORTED OUTCOMES25
PREVALENCE OF OCCULT UROLOGIC MALIGNANCIES IN PATIENTS UNDERGOING SCREENING FOR LUNG CANCER25
REAL-WORLD ANALYSES OF MACE AND MORTALITY RISK IN PATIENTS WITH PROSTATE CANCER AFTER INITIATION OF LHRH AGONISTS VS. GNRH ANTAGONIST25
COMUTATIONAL PATTERNS IN FGFR3-ALTERED NON-MUSCLE INVASIVE BLADDER CANCER INFLUENCE RECURRENCE AND PROGRESSION24
Exploring prostate-specific antigen (PSA) Testing rates and screening disparities in the all of us dataset24
Carbonic anhydrase 10 functions as a tumor suppressor in renal cell carcinoma and its methylation is a risk factor for survival outcome24
DECIPHER® GENOMIC CLASSIFIER SCORE ON INITIAL BIOPSY IS ASSOCIATED WITH PROGRESSION FORM ACTIVE SURVEILLANCE TO TREATMENT IN PROSTATE CANCER24
“Published abstracts from the 24th Annual Meeting of the Society of Urologic Oncology”24
Editorial Board23
The role of enhanced recovery after surgery protocols in the development of acute kidney injury following radical cystectomy23
Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-323
National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy23
Safety and efficacy of intravesical Bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer: A retrospective study22
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study22
Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns22
Multicenter study of active surveillance for small renal masses: Real world practice pattern22
Morbidity and mortality of multivisceral resection with radical nephrectomy for locally advanced renal cell carcinoma: An analysis of the National Surgical Quality Improvement Program (NSQIP) database21
Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma21
Cover 2 - Masthead21
Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer20
Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy20
Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy20
Is YouTube a good resource for patients to better understand kidney cancer?20
Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens20
Methodological considerations for systematic review and meta-analysis of Xpert bladder cancer monitor20
Predictive value of renal tumor contour irregularity score in pathological T3a upstaging of clinical T1 renal cell carcinoma: A multi-institutional study19
Comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: is AUC close enough to clinical practice?19
Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collabor19
Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma19
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma19
PSA kinetics and predictors of PSA response in metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors18
Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer18
Managing female sexual dysfunction18
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-0218
The centralization of bladder cancer care and its implications for patient travel distance18
FACTORS ASSOCIATED WITH PROSTATE CANCER SCREENING AMONG HISPANIC MEN: RESULTS FROM HISPANIC COMMUNITY HEALTH STUDY/STUDY OF LATINOS (HCHS/SOL)17
IMMEDIATE LYMPHATIC RECONSTRUCTION WITH LYMPHATICOVENOUS BYPASS CREATION AFTER BILATERAL INGUINAL LYMPH NODE DISSECTION FOR PENILE CANCER: A CASE SERIES17
Multivariate analysis of the parameters affecting the choice of surgical treatment for patients with localized renal cell carcinoma (RCC)17
AUTOMATED NEPHROMETRY SCORES THROUGH DIRECT PREDICTION OF EACH COMPONENT17
TUMOROID AND GENOMIC MODELING OF LOW GRADE INTERMEDIATE RISK BLADDER CANCER TO PREDICT INTRAVESICAL CHEMOTHERAPY RESPONSE17
Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance17
CLINICAL PROGRESSION OF PROSTATE CANCER FROM ACTIVE SURVEILLANCE IS PREDICTED BY DECIPHER® GENOMIC CLASSIFIER SCORE ON INDEX BIOPSY INDEPENDENT FROM RISK ASSESSMENT BY MRI CHARACTERISTICS17
Number of cores needed to diagnose prostate cancer during MRI targeted biopsy decreases after the learning curve16
Radiation therapy in the management of the inguinal region in penile cancer: What's the evidence?16
Chronic kidney disease and radical cystectomy for bladder cancer: perioperative and oncologic outcomes in 1,214 patients16
A comparison of outcomes between transperitoneal and retroperitoneal robotic assisted partial nephrectomy in patients with completely endophytic kidney tumors16
Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis16
Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prosp16
Prospective validation of clino-radio-pathological risk scoring system (CRiSS) for prediction of inguinal lymph-nodes metastasis in squamous cell carcinoma of penis16
Molecular mechanism of microRNAs, long noncoding RNAs, and circular RNAs regulating lymphatic metastasis of bladder cancer15
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank15
A polygenic risk score is associated with risk of bladder cancer and earlier age of diagnosis, independent of lifestyle factors15
Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity14
The impact of bladder cuff excision on outcomes after nephroureterectomy for upper tract urothelial carcinoma: An analysis of the ROBUUST 2.0 registry14
Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists’ ever-expanding differential diagnosis for a heterogeneous group of entities14
Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non–muscle invasive bladder cancer14
Healthcare costs and resource utilization associated with renal cell carcinoma among older Americans: A longitudinal case-control study using the SEER-Medicare data14
Corrigendum to: Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy14
EDARADD silencing suppresses the proliferation and migration of bladder cancer cells14
Multimodality treatment of penile cancer: Part 214
Impact of the time elapsed between prostate biopsy and surgery on the accuracy of nomograms predicting lymph node invasion in patients with clinically localized prostate cancer14
Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor13
IMPACT OF NODAL DISEASE IN NON-CLEAR CELL RENAL CELL CARCINOMA AND THE ROLE OF SALVAGE LYMPH NODE RESECTION13
CHEST CT SHOULD REPLACE CHEST X-RAYS TO EVALUATE FOR THORACIC RENAL CELL CARCINOMA METASTASES13
RETROPERITONEAL NODAL DISTRIBUTION OF METASTATIC SEMINOMA: A CLINICAL MAPPING STUDY13
Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT)13
UTILIZING LOW-PASS WHOLE GENOME SEQUENCING OF URINARY-TUMOR DNA TO IDENTIFY MINIMAL RESIDUAL DISEASE PRIOR TO REPEAT TRANSURETHRAL RESECTION OF BLADDER TUMOR13
INTENSIFIED MRI-BASED PROSTATE CANCER SCREENING IN GERMLINE CARRIERS OF RARE PATHOGENIC VARIANTS: INTERIM RESULTS FROM THE INITIAL SCREENING ROUND OF THE PROGRESS STUDY13
Conditional survival of stage III non-seminoma testis cancer patients13
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety13
Comparison of microwave ablation and partial nephrectomy for T1a small renal masses13
PSYCHOLOGICAL RESILIENCE AND DISTRESS AMONG RADICAL CYSTECTOMY PATIENTS: A SYMPTOM DISTRESS SCALE SURVEY ANALYSIS13
DEFINING THE IMPACT OF PERSONAL AND FAMILY HISTORY OF LYNCH-SYNDROME ASSOCIATED CANCERS ON CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA13
COMPARING WHITE LIGHT VERSUS BLUE LIGHT CYSTOSCOPY RECURRENCE OUTCOMES AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS IN AN EQUAL ACCESS SETTING: A PROPENSITY SCORED MATCHED ANALYSIS13
FEASIBILITY AND OUTCOMES OF INTERVENTIONS TO REDUCE CYSTOSCOPY DISCOMFORT: A QUALITY IMPROVEMENT PILOT13
Exploring the tumor-promoting function and prognostic value of ESPL1 in prostate adenocarcinoma13
Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database12
Nivolumab plus gemcitabine–cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial12
Re: Hera et al. impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus12
MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) OF LOCALIZED PROSTATE CANCER: SINGLE INSTITUTION EXPERIENCE OF TREATMENT EFFICACY12
Prostate magnetic resonance imaging utilization and its relationship with advanced prostate cancer detection12
HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center12
Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients12
Diagnostic performance of 68Ga-PSMA-11 PET/MRI in biochemical recurrent prostate cancer after radical prostatectomy and prediction nomogram12
Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma12
Cover 2 - Masthead12
Editorial Board12
Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center12
Pathologic and Short-Term Oncologic Outcomes of Prostate Cancer Patients Following Transvesical Robot-Assisted Radical Prostatectomy12
Morbidity and mortality of salvage radical prostatectomy for prostate cancer: An analysis of the National surgical quality improvement program targeted prostatectomy database12
Assessing the sex-based enrollment gap in urologic oncology clinical trials12
Understanding the role of statin use on advanced prostate cancer outcomes: Does the statin type, cumulative dose, or duration impact survival?12
Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma12
Unraveling the BMI paradox in different renal cortical tumors: insights from the INMARC registry12
SURVIVAL PATTERNS BASED ON SITE-SPECIFIC VISCERAL METASTASIS IN METASTATIC PROSTATE CANCER PATIENTS: ARE OUTCOMES OF VISCERAL METASTASES THE SAME?11
LOW-GRADE AND HIGH-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER RESPOND DIFFERENTLY TO BACILLUS CALMETTE-GUÉRIN AND GEMCITABINE-DOCETAXEL11
Editorial Board11
Development of a specific supportive care needs scale for radical cystectomy patients and its reliability and validity test11
The 5-item frailty index predicts 30-day morbidity and mortality in radical nephrectomy patients: A propensity matched analysis11
Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection11
Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma11
Diagnostic performance of Cxbladder Triage Plus for the identification and stratification of patients at risk for urothelial carcinoma: The multicenter, prospective, observational DRIVE study11
Commentary on: “Adjuvant vs. salvage radiotherapy in men with pathologically node-positive prostate cancer after radical prostatectomy”11
Leveraging DNA repair deficiency to personalize radiopharmaceutical therapy in prostate cancer11
Table of Contents11
Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer11
Acetyl-CoA synthetase 2 enhances tumorigenesis and is indicative of a poor prognosis for patients with renal cell carcinoma11
Uptake of re-resection in T1 bladder cancer: An interrupted population-based time series analysis among different groups of surgeons11
LARGE LANGUAGE MODEL FOR PROVIDING PATIENT-FOCUSED GUIDANCE FOLLOWING RADICAL PROSTATECTOMY11
BLOOD-BASED LIQUID BIOPSY IN DIAGNOSIS, SURVEILLANCE, AND PROGNOSIS OF PATIENTS WITH PRIMARY UPPER TRACT UROTHELIAL CARCINOMA11
State of the Art: The Microbiome in Bladder Cancer11
PHASE 3 MK-5684-004 STUDY OF CYP11A1 INHIBITOR OPEVESOSTAT VERSUS NEXT-GENERATION HORMONAL AGENT (NHA) SWITCH IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER 1 PRIOR NHA11
Masculinity stigma and metastatic prostate cancer: A review with a focus on Latin America11
Device-related complications during renal cryoablation: insights from the Manufacturer and User Facility Device Experience (MAUDE) database11
Cover 2 - Masthead11
Development of a predictive model for recurrence-free survival in pTa low-grade bladder cancer11
Characteristics Contributing to Survival Differences Between Black and White Patients Following Cystectomy11
CHANGES IN PROSTATE SPECIFIC ANTIGEN SCREENING FOLLOWING THE 2018 UNITED STATES PREVENTIVE SERVICES TASK FORCE GUIDELINES AND THROUGH THE COVID-19 PANDEMIC11
PSMA PET/CT-DETECTED MESORECTAL LYMPH NODE METASTASES: TREATMENT OUTCOMES AND CLINICAL IMPLICATIONS11
Disparities in access to high-volume centers and in hospital discharge status following radical cystectomy in Florida10
Pattern and risk factors of local recurrence and intravesical recurrence after segmental ureterectomy for upper tract urothelial carcinoma10
Assessing the impact of lymphovascular invasion on overall survival in surgically treated renal cell carcinoma patients: A nationwide cohort analysis10
Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide10
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention10
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy10
Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: A scoping review10
Evaluation of short term surgical outcomes of radical prostatectomy in the decade following the introduction of minimum volume standards in the Netherlands10
Biodynamic prediction of neoadjuvant chemotherapy response: Results from a prospective multicenter study of predictive accuracy among muscle-invasive bladder cancer patients10
Contemporary outcomes for robotic radical cystectomy and intracorporeal neobladder urinary diversion10
Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma10
Bilateral inguinal lymphadenectomy using simultaneous double laparoscopies for penile cancer: A retrospective study10
Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy10
Opioid prescription following radical orchiectomy associated with new persistent opioid use10
2024 Star Reviewers for Urologic Oncology10
Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET10
Comparative analysis of salvage partial nephrectomy versus radical nephrectomy after the failure of initial partial nephrectomy10
Investigating the pattern of prostate specific antigen screening among E-cigarette smokers within the behavioral risk factor surveillance system9
INTRAVESICAL AUTOLOGOUS TIL THERAPY IN BCG-EXPOSED NMIBC: A REPORT OF EARLY SAFETY AND EFFICACY FINDINGS9
EARLY POSTOPERATIVE CANCER-SPECIFIC DEATH AMONGST PATIENTS WITH HIGH-RISK NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA: REFINING RISK STRATIFICATION TO OPTIMIZE SELECTION FOR ADJUVANT THERAPY9
THE PROGNOSTIC SIGNIFICANCE OF CIRCULATING TUMOR DNA IN PATIENTS WITH POSITIVE LYMPH NODE DISEASE AFTER ROBOTIC-ASSISTED RADICAL CYSTECTOMY9
Intra-arterial chemotherapy combined with BCG immunotherapy is more effective than intra-arterial chemotherapy plus intravesical chemotherapy or standard BCG immunotherapy in preventing the recurrence9
THE PROGNOSTIC ROLE OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS TREATED WITH INTRAVESICAL GEMCITABINE AND DOCETAXEL9
Clinically significant prostate cancer detection rate in biopsy-naïve patients with mpMRI and microultrasound topographically discordant lesions: A single-center retrospective analysis9
Editorial Board9
Table of Contents9
INCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE F9
Thermal ablation for local tumor recurrence after previous partial nephrectomy: Perioperative and oncological outcomes9
MAPPING PATTERNS OF RECURRENCE AFTER SALVAGE LYMPH NODE DISSECTION IN PATIENTS WITH METASTATIC PROSTATE CANCER9
Association of heavy metals and trace elements in renal cell carcinoma: A case-controlled study9
LEVEL OF NODAL METASTASIS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY AND LYMPHADENECTOMY: IS THERE A ROLE OF EXTENDED LYMPHADENECTOMY IN THE POST-S1011 ERA?9
Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer9
Prognostic significance of pathologic response to neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder with histologic subtype9
Predictive factors for recurrence and outcomes in T1a renal cell carcinoma: Analysis of the INMARC (International Marker Consortium for Renal Cancer) database9
THE NONCANONICAL WNT PATHWAY (FYN/STAT3) ACTIVATED BY YY1 PROMOTES THE NEUROENDOCRINE DIFFERENTIATION OF PROSTATE CANCER CELLS.9
Development of point-of-care tests for urinary bladder cancer – an historic review and view to future prospectives9
QUANTIFYING THE BENEFIT OF SALVAGE RADIATION THERAPY FOR BIOCHEMICALLY RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY9
2023 Star Reviewers for Urologic Oncology9
Mutational landscape of non-muscle-invasive bladder cancer9
Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: A network meta-analysis9
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment9
EARLY ONCOLOGIC OUTCOME AND PSA KINETICS FOLLOWING IRREVERSIBLE ELECTROPORATION IN MEN WITH PROSTATE CANCER8
“I was in a very deep, dark place... I wasn't prepared for that”: A qualitative assessment of the emotional well-being needs of patients undergoing cystectomy8
A machine learning approach to predict progression on active surveillance for prostate cancer8
The efficacy of adjuvant mitotane therapy and radiotherapy following adrenalectomy in patients with adrenocortical carcinoma: A systematic review and meta-analysis8
Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma8
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer8
The relationship between BCG immunotherapy and oxidative stress parameters in patients with nonmuscle invasive bladder cancer8
Cover 2 - Masthead8
PIVOT-006: A PHASE 3, RANDOMIZED STUDY OF ADJUVANT INTRAVESICAL CRETOSTIMOGENE GRENADENOREPVEC VERSUS SURVEILLANCE FOR THE TREATMENT OF INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER8
DEVELOPMENT AND EXTERNAL VALIDATION OF A LOCAL PELVIC RECURRENCE RISK SCORE AFTER RADICAL CYSTECTOMY: IDENTIFYING THE IDEAL CANDIDATE FOR ADJUVANT RADIATION CLINICAL TRIALS8
THE ASSOCIATION BETWEEN HEALTH LITERACY AND ALL-CAUSE MORTALITY IN UROLOGIC CANCER PATIENTS8
Clinical outcomes of retreatment or discontinuation after interruption of nivolumab plus ipilimumab due to immune-related adverse events in metastatic renal cell carcinoma patients: A retrospective mu8
Artificial intelligence in prostate cancer: Definitions, current research, and future directions8
HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY OR OTHER SUBTYPES NOT A PREDICTOR FOR PROGRESSION IN BCG-TREATED PATIENTS8
Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential8
A PHASE IIB RANDOMIZED PLACEBO-CONTROLLED TRIAL TESTING A LONG-CHAIN OMEGA-3 FATTY ACID MAG-EPA DIETARY SUPPLEMENT ON PROSTATE CANCER AND GUT MICROBIOME8
The role of autophagy dysregulation in low and high-grade nonmuscle invasive bladder cancer: A survival analysis and clinicopathological association8
RISK FACTORS FOR PROGRESSION IN PATIENTS WITH POST-BCG RECURRENT NMIBC8
THE DISPARITY OF LYMPH NODE DISSECTION IN T2+N0M0 STAGE PENILE SQUAMOUS CELL CARCINOMA PATIENTS8
Michael Droller: An appreciation, for his Festschrift 20248
Liquid biopsy testing in urological cancers: Focus on urine8
Steroidogenesis in castration-resistant prostate cancer8
Rates of volume reduction after selective arterial embolization for renal angiomyolipoma8
Diagnostic yield of upper tract imaging performed for hematuria screening: Results from a national, privately-insured cohort8
Annular-shaped stenosis in the ureter: Caution should be taken8
Deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma: A systematic review and patient-level meta-analysis8
Intra-arterial chemotherapy plus BCG, a promising combination adjuvant treatment for high-risk NMIBC8
Avoiding “Needless” nephrectomy: What is the role of small renal mass biopsy in 2024?8
STIMULATED RAMAN HISTOLOGY AND ARTIFICIAL INTELLIGENCE ALLOWS FOR PREDICTION OF PROSTATE CANCER EXTRAPROSTATIC EXTENSION AND POSITIVE SURGICAL MARGIN DURING RADICAL PROSTECTOMY8
UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer8
Contemporary morbidity and mortality of open versus robotic cystectomy for bladder cancer: An analysis of the National Surgical Quality Improvement Program (NSQIP) procedure targeted cystectomy databa8
Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis7
Clinician interest in clinical decision support for PSA-based prostate cancer screening7
Does neoadjuvant chemotherapy diminish the sex disparity in bladder cancer survival after radical cystectomy?7
COMPARING ACTIVE SURVEILLANCE AND WATCHFUL WAITING AND RADICAL TREATMENT USING MACHINE LEARNING MODELS AMONG PROSTATE CANCER PATIENTS7
Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab7
Transperineal 3T MRI-guided and transrectal MRI-ultrasound fusion prostate biopsies: Do lesion location and size impact diagnostic yield?7
Metformin intake and risk of metabolic acidosis after radical cystectomy with urinary diversion: A comparative study using data from the TriNetX research network7
Comparison of oncologic outcomes following robot-assisted radical prostatectomy in high- and very high-risk prostate cancer based on the 2025 National Comprehensive Cancer Network risk stratification7
Beyond tunnel vision – reconsidering real-world evidence on staging in intermediate-risk prostate cancer7
Comparative study of postoperative complications after radical cystectomy during the past two decades in Japan: Radical cystectomy remains associated with significant postoperative morbidities7
Global trends and regional variations in PCa burden: A focus on China's rapid growth7
The CAG-triplet in the androgen receptor gene and single-nucleotide polymorphisms in androgen pathway genes in patients with concomitant bladder and prostate cancer7
A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy—A large, retrospective, single-center study7
Surgical templates for inguinal lymph node dissection in cN0 penile cancer: A comparative study7
Palliative and hospice care in prostate cancer: A scoping review7
Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma7
CARCINOMA IN SITU AND URINARY CYTOLOGY AS AN INDICATOR OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BCG7
SEQUENTIAL ENDOLUMINAL GEMCITABINE AND CABAZITAXEL WITH SYSTEMIC PEMBROLIZUMAB FOR RECURRENT NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE UPPER AND LOWER URINARY TRACTS7
Cause-specific mortality among patients with renal cell carcinoma in the United States from 2000 to 20187
Single dose perioperative intravesical instillation of gemcitabine versus mitomycin-C following resection of non-muscle invasive bladder cancer: A randomized controlled trial7
HOME INSTILLATION OF UGN-102 FOR PRIMARY CHEMOABLATION OF RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER: A SINGLE-ARM, OPEN-LABEL, PHASE 3B TRIAL7
ONCOLOGIC OUTCOMES OF BLADDER-SPARING MANAGEMENT FOR HIGH-GRADE NON-INVASIVE UROTHELIAL CARCINOMA OF THE PROSTATIC URETHRA7
Bladder cancer patient and provider perspectives on smoking cessation7
Can Retroperitoneal Lymph Node Dissection (RPLND) be feasibly performed to prolong survival in Renal Cell Carcinoma (RCC) with limited lymph node involvement? An Analysis of Recurrence Patterns7
Oncogenic MicroRNAs: Key players in human prostate cancer pathogenesis, a narrative review7
Second line salvage systemic therapy for advanced penile cancer7
Influence of radical prostatectomy on miRNA dynamics in urine extracellular vesicles7
Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysis7
GRADE AND VOLUME PROGRESSION AND ITS ASSOCIATION WITH THE DECIPHER GENOMIC CLASSIFIER USING PATIENTS ENROLLED IN A PROSPECTIVE ACTIVE SURVEILLANCE PROTOCOL7
Cover 2 - Masthead7
Re: Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer. Yanagisawa T, Sato S, Hayashida Y, Okada Y, Fukuokaya W, Iwatani K, et al. J Urol Oncol. 2023;41(12):484.e7-484.e157
Multigenerational VHL family characterized by pathogenic germline ELOC variant: Response to belzutifan7
A mindful approach to complications: Brief review of the literature and practical guide for the surgeon7
Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions7
Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis7
HPV and urological cancers: Investigating renal and prostate cancer associations7
Update on organ preserving surgical strategies for penile cancer7
Revisiting BCG: The potential of rescue BCG therapy for BCG-unresponsive non-muscle-invasive bladder cancer7
Variant histology in upper tract carcinomas: Analysis of the National Cancer Database6
CONCOMITANT SECOND-GENERATION HORMONE THERAPY WITH RADIUM-223 IN THE THIRD-LINE SETTING: DOES IT IMPROVE OVERALL SURVIVAL?6
DEVELOPMENT AND TESTING OF A CUSTOM NANOSTRING RNA CODESET FOR MUSCLE-INVASIVE BLADDER CANCER UTILIZING TCGA SUBTYPING (SWOG S1011)6
0.039128065109253